Skip to content

The Actual News

Stay informed without the news wearing you out.

FDA Approves New Breast Cancer Pill After Hormone Therapy Stops Working

FDA Approves New Breast Cancer Pill After Hormone Therapy Stops Working

Summary

The FDA approved once-daily giredestrant with everolimus for certain people with advanced, estrogen-receptor-positive, HER2-negative breast cancer that worsened after hormone therapy. The approval covers tumors with ESR1 mutations, which can make hormone treatments less effective; a blood test can identify these mutations. In a clinical trial, the combination delayed cancer worsening compared with standard hormone therapy, but its effect on overall survival is not yet known.

Key Facts

  • The treatment combines giredestrant with everolimus.
  • The approval applies to advanced ER-positive, HER2-negative breast cancer with ESR1 mutations that worsened after hormone therapy.
  • The FDA also approved the FoundationOne Liquid CDx blood test to identify tumor DNA associated with ESR1 mutations.
  • The trial included 373 adults, 207 of whom had ESR1 mutations.
  • Among patients with ESR1 mutations, median time before cancer worsened was 10 months with giredestrant and everolimus, compared with 5.5 months with standard hormone therapy.
  • Tumors shrank in 27 percent of patients receiving the combination and 14 percent receiving standard hormone therapy.
  • The treatment’s effect on overall survival remains unknown.
  • Reported adverse reactions included mouth or lung-tissue inflammation, rash, fatigue, diarrhea, musculoskeletal pain, and nausea; the label also warns about slow heartbeat and fetal harm.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.